Clinical

Dr. Rachel Brem joins Breathe BioMedical as Executive Director and Chief Medical Officer

Retrieved on: 
Tuesday, January 9, 2024

MONCTON, NB, Jan. 9, 2024 /PRNewswire/ - Breathe BioMedical (BBM) is pleased to announce the appointment of Dr. Rachel Brem to the company's Board of Directors in her newly appointed role of Executive Director and Chief Medical Officer.

Key Points: 
  • MONCTON, NB, Jan. 9, 2024 /PRNewswire/ - Breathe BioMedical (BBM) is pleased to announce the appointment of Dr. Rachel Brem to the company's Board of Directors in her newly appointed role of Executive Director and Chief Medical Officer.
  • Dr. Brem is a world-renowned expert in breast cancer and the Director of the Breast Imaging and Interventional Center at the George Washington University.
  • Dr. Brem is the Chief Medical Officer of the Brem Foundation, a 501(c) 3 which began nearly 20 years ago, inspired by her mission and life story that is dedicated to the early detection of breast cancer.
  • "We are excited to have Dr. Brem's leadership at the Executive Director level to lead our Clinical and Regulatory strategy as our Chief Medical Officer."

Welcome to SciBase Capital Markets Day 2024

Retrieved on: 
Tuesday, January 9, 2024

STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.

Key Points: 
  • STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.
  • During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals.
  • The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets.
  • Two external speakers will participate in the event, further supporting the US role in the SciBase strategy going forward.

The Inner Circle Acknowledges, Anika Chowhan as a Trusted Healthcare Professional

Retrieved on: 
Monday, January 8, 2024

CHOWHAN, Md., Jan. 8, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Anika Chowhan is acknowledged as a Most Trusted Healthcare Professional for her contributions to Pediatrics.

Key Points: 
  • CHOWHAN, Md., Jan. 8, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Anika Chowhan is acknowledged as a Most Trusted Healthcare Professional for her contributions to Pediatrics.
  • Dr. Chowhan received a Bachelor of Arts degree at the University of Berkeley and earned a Medical Degree from Baylor College of Medicine.
  • She is an expert in General Pediatrics and practices in Manassas VA.
  • The doctor specializes in the health care of children and notes that a pediatrician diagnoses and treats infections, injuries, diseases, and other disorders in children.

Affimed Announces Leadership Change and Organizational Restructuring

Retrieved on: 
Monday, January 8, 2024

Dr. Hoess joined Affimed in October 2010 and has served as its Chief Executive Officer since September 2011.

Key Points: 
  • Dr. Hoess joined Affimed in October 2010 and has served as its Chief Executive Officer since September 2011.
  • "On behalf of Affimed, I would like to thank Adi for his dedication to the Company.
  • "On behalf of Affimed, I wish Adi all the best in his future endeavors."
  • Key highlights of the restructuring plan include:
    Focus on Clinical Programs: Affimed will direct all resources towards advancing the development of its clinical programs.

Accenture Invests in QuantHealth to Accelerate Use of AI-powered Clinical Trial Simulations to Drive Cost-Effective Drug Development

Retrieved on: 
Monday, January 8, 2024

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    With proprietary AI technology trained on a massive dataset of 350 million patients, large biomedical knowledge-graphs, and clinical trial data, QuantHealth’s simulation platform can predict trial outcomes with significant accuracy.
  • “QuantHealth’s clinical trial simulation platform can fast-track clinical trials and help pharmaceutical and biotech companies bring life-saving treatments to patients” said Tom Lounibos, global lead of Accenture Ventures.
  • QuantHealth is already working with several global pharmaceutical companies to use its product in clinical trial design and development.
  • “QuantHealth has created a solution that uses AI to transform how pharmaceutical companies approach their clinical trials.

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Retrieved on: 
Friday, January 5, 2024

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.i The FDA approved ZELSUVMI as the first novel drug for the treatment of molluscum infections.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.i The FDA approved ZELSUVMI as the first novel drug for the treatment of molluscum infections.
  • vi
    “It is nice to see that molluscum contagiosum is finally getting the attention it deserves.
  • Nitric oxide has been shown to have antiviral properties.vii The mechanism of action of ZELSUVMI for the treatment of molluscum contagiosum is unknown.
  • With ZELSUVMI, patients now have an at-home treatment option available.”
    ZELSUVMI is expected to be available in the United States in the second half of 2024.

K2 Medical Research Join Forces with Magruder Eye Institute to Advance Alzheimer's Clinical Trial Accessibility Through RetiSpec's AI-Driven Eye Test

Retrieved on: 
Wednesday, January 3, 2024

ORLANDO, Fla., Jan. 3, 2024 /PRNewswire/ -- K2 Medical Research, a privately-owned clinical research facility in the greater Orlando area, has teamed up with Magruder Eye Institute and RetiSpec in a research pilot to enhance access to clinical trials.

Key Points: 
  • ORLANDO, Fla., Jan. 3, 2024 /PRNewswire/ -- K2 Medical Research, a privately-owned clinical research facility in the greater Orlando area, has teamed up with Magruder Eye Institute and RetiSpec in a research pilot to enhance access to clinical trials.
  • K2 Medical Research , renowned for its expertise in managing and conducting clinical trials, brings valuable insights and support to the research collaboration.
  • The partnership with Magruder Eye Institute, a distinguished eye care institution known for its commitment to patient care and cutting-edge research, signifies a pivotal step toward expanding the reach of clinical trials within eye care settings.
  • "This collaboration marks a significant milestone in our commitment to advancing medical research and improving the accessibility of clinical trials," says Sean Stanton, Founder of K2 Medical Research.

American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event

Retrieved on: 
Wednesday, January 3, 2024

Primary Prevention of Heart Attacks: The Clinical and Economic Benefits of Epi+Gen CHD

Key Points: 
  • Primary Prevention of Heart Attacks: The Clinical and Economic Benefits of Epi+Gen CHD
    Every year, about 805,000 people in the United States have a heart attack, with someone experiencing a heart attack every 40 seconds.
  • Heart disease is the leading cause of death for both men and women.
  • In peer-reviewed studies, Epi+Gen CHD was more cost-effective and more sensitive for assessing heart attack risk compared to standard lipid-based risk calculators.
  • Cardio Diagnostics continues to lead the way in precision cardiovascular medicine, leveraging the power of AI and epigenetics to help prevent heart attacks.

Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials

Retrieved on: 
Tuesday, January 2, 2024

WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report initial clinical data from its Phase 1/2 ACHIEVE and DELIVER trials on January 3, 2024, and to host a virtual event at 8:00 a.m.

Key Points: 
  • WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced it plans to report initial clinical data from its Phase 1/2 ACHIEVE and DELIVER trials on January 3, 2024, and to host a virtual event at 8:00 a.m.
  • The company intends to issue a press release prior to the start of the event.
  • The live event webcast will be available in the Events & Presentations page of the Investors & Media section of Dyne’s website and a replay will be accessible for 90 days following the presentation.
  • To register for the live webcast and replay, please visit https://investors.dyne-tx.com/news-and-events/events-and-presentations .

Novel Device Facilitates Successful No-Shave FUE Transplants for Long Hair with Ease

Retrieved on: 
Tuesday, January 2, 2024

The newly introduced UGraft Zeus® device significantly streamlines the procedure, making it faster and easier while minimizing graft damage.

Key Points: 
  • The newly introduced UGraft Zeus® device significantly streamlines the procedure, making it faster and easier while minimizing graft damage.
  • It resulted in a lower graft damage rate (2.2-4.3%) compared to previously published studies (5.6% - 9.2%), alongside an unprecedented 87% long hair graft retrieval.
  • The device's versatility was further demonstrated in the study by its success in performing no-shave long hair FUE in black patients of African descent, who are typically deemed challenging in even shaved head FUE procedures.
  • The UGraft Zeus® now extends hope to patients unable to shave their heads due to lifestyle or cost constraints in accessing long hair FUE.